Table 4.
Overall survival in univariate and multivariate analyses
| Variables | Median (95% CI) | P-value | |
|---|---|---|---|
| Univariate | Multivariate | ||
| Age (years) | 0.045 | 0.092 (HR: 0.67, 95% CI: 0.12–1.22) | |
| ≥65 | 9.2 (8.25–10.15) | ||
| <65 | 6.6 (5.66–7.54) | ||
| Gender | 0.704 | ||
| Female | 8.2 (7.62–8.78) | ||
| Male | 8.2 (6.13–10.27) | ||
| Smoking history | 0.999 | ||
| Smoker | 8.2 (6.05–10.35) | ||
| Non-smoker | 8.8 (7.8–9.8) | ||
| ECOG performance status | 0.119 | ||
| 0–1 | 9.4 (7.9–10.87) | ||
| ≥2 | 8 (6.01–9.99) | ||
| Pathological type | 0.364 | ||
| Adenocarcinoma | 8 (6.37–9.63) | ||
| Non-adenocarcinoma | 9.4 (8.22–10.58) | ||
| Line of apatinib | 0.123 | ||
| Second line | 9.4 (6.62–12.18) | ||
| Further line | 8.2 (5.93–10.47) | ||
| Location | 0.971 | ||
| Central | 8.2 (6.28–10.12) | ||
| Peripheral | 8.5 (7.48–9.52) | ||
| Apatinib-induced hypertension | 0.005 | 0.022 (HR: 0.45, 95% CI: 0.23–0.89) | |
| Yes | 9.9 (7.9–10.8) | ||
| No | 7.8 (4.98–8.62) | ||
Abbreviation: ECOG, Eastern Cooperative Oncology Group.